Etavopivat

DB18176InvestigationalSmall molecule

Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for the treatment of sickle cell disease.

Chemical structure of Etavopivat
Mechanism
Curator reviewed
Formula / weight
C22H23N3O6S · 457.5 g/mol (avg)
Code names
FT-4202

Resolves to

Compound
UNIIV4E0A9M44QCAS2245053-57-8ChEMBLCHEMBL4650332
Structure
InChIKeyKZFFYEPYCVDOGE-LJQANCHMSA-NSMILESOC[C@@H](C(=O)N1CC2=C(C1)CN(C2)S(=O)(=O)C1=CN=C2OCCOC2=C1)C1=CC=CC=C1
Targets
P30613PKLR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
11Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Etavopivat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In